ICH Guidelines and Regulatory Perspective
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) publishes the internationally harmonised...
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) publishes the internationally harmonised guidelines that govern the quality, safety, and efficacy data required to support pharmaceutical regulatory submission across major global markets, and several ICH guideline series are of direct and recurring relevance to medicinal chemistry practice. The ICH Q-series addresses pharmaceutical quality, including Q2(R2) analytical method validation (addressed in detail in Phase 4 of this text), Q3A/Q3B impurity qualification thresholds, and Q3C residual solvent classification, all of which directly shape how a medicinal chemist designs and validates the synthetic and analytical work described throughout this text. The ICH M-series, including M7 addressing mutagenic impurity control, and the S-series addressing non-clinical safety testing, similarly intersect with medicinal chemistry practice wherever a synthetic route or structural modification carries implications for impurity profile or genotoxic risk. A working understanding of this regulatory framework is not a peripheral concern for the medicinal chemist but a design constraint that shapes synthetic route selection, purification strategy, and structural modification decisions from the earliest stages of a discovery programme.
Chapter Summary
This introductory phase has established the conceptual and regulatory foundation of medicinal chemistry: its definition and interdisciplinary scope, the sequential drug discovery process from target identification through lead optimization, the major classes of druggable biological targets, the ADMET concept underlying candidate attrition, the extended drug development pipeline that follows discovery, and the ICH regulatory framework that shapes medicinal chemistry practice throughout. With this foundation established, Phase 1 turns to the first practical stage of the discovery workflow: computational drug design and molecular docking.